Now, it’s worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

Analysts say this approval could significantly expand Alhemo's market potential. The hemophilia space is becoming increasingly competitive with gene therapies and new clotting factor treatments, but Novo Nordisk's broader label should reinforce its rare disease portfolio.